NeoGenomics, Inc. General Counsel Sells 79,488.00 in Stock

NEO Stock  USD 17.73  0.01  0.06%   
About 51% of NeoGenomics' investor base is interested to short. The analysis of overall sentiment of trading NeoGenomics stock suggests that many investors are impartial at this time. NeoGenomics' investing sentiment overview a quick insight into current market opportunities from investing in NeoGenomics. Many technical investors use NeoGenomics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
NeoGenomics, Inc. General Counsel Alicia C. Olivo sold 5,175 shares of the firms stock in a transaction on Friday, November 15th. The shares were sold at an average price of 15.36, for a total value of 79,488.00. Following the completion of the sale, the general counsel now owns 37,129 shares

Read at thelincolnianonline.com
news
  

NeoGenomics Current Investor Sentiment

Panic Vs Confidence

49

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use NeoGenomics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward NeoGenomics.

NeoGenomics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards NeoGenomics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

NeoGenomics Fundamental Analysis

We analyze NeoGenomics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NeoGenomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NeoGenomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Working Capital

Working Capital Comparative Analysis

NeoGenomics is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

NeoGenomics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with NeoGenomics stock to make a market-neutral strategy. Peer analysis of NeoGenomics could also be used in its relative valuation, which is a method of valuing NeoGenomics by comparing valuation metrics with similar companies.

Peers

NeoGenomics Related Equities

ACRSAclaris Therapeutics   6.54   
0%
100.0%
TWSTTwist Bioscience   1.78   
0%
27.0%
GHGuardant Health   1.45   
0%
22.0%
BDSXBiodesix   0.70   
0%
10.0%
MTDMettler Toledo   0.63   
0%
9.0%
SHCSotera Health   0.53   
0%
8.0%
NEOGNeogen   0.28   
0%
4.0%
MYGNMyriad Genetics   0.06   
1.0%
0%
CRLCharles River   0.27   
4.0%
0%
IQVIQVIA Holdings   0.29   
4.0%
0%
NTRANatera   0.40   
6.0%
0%
CSTLCastle Biosciences   0.53   
8.0%
0%
QGENQiagen NV   0.73   
11.0%
0%
ICLRICON PLC   1.22   
18.0%
0%
CDNACaredx   1.49   
22.0%
0%
When determining whether NeoGenomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NeoGenomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neogenomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neogenomics Stock:
Check out NeoGenomics Hype Analysis, NeoGenomics Correlation and NeoGenomics Performance.
To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.306
Earnings Share
(0.61)
Revenue Per Share
5.098
Quarterly Revenue Growth
0.104
Return On Assets
(0.03)
The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.